Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Investment Income (2020 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Non Operating Investment Income for 4 consecutive years, with -$69000.0 as the latest value for Q4 2023.

  • Quarterly Non Operating Investment Income fell 592.86% to -$69000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$61000.0 through Dec 2023, up 87.05% year-over-year, with the annual reading at -$61000.0 for FY2023, 87.05% up from the prior year.
  • Non Operating Investment Income hit -$69000.0 in Q4 2023 for Insight Molecular Diagnostics, up from -$89000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $315000.0 in Q4 2020 to a low of -$330000.0 in Q1 2022.
  • Historically, Non Operating Investment Income has averaged -$312.5 across 4 years, with a median of -$7000.0 in 2021.
  • Biggest YoY gain for Non Operating Investment Income was 981.25% in 2021; the steepest drop was 790.0% in 2021.
  • Year by year, Non Operating Investment Income stood at $315000.0 in 2020, then plummeted by 106.03% to -$19000.0 in 2021, then surged by 173.68% to $14000.0 in 2022, then crashed by 592.86% to -$69000.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for IMDX at -$69000.0 in Q4 2023, -$89000.0 in Q3 2023, and -$24000.0 in Q2 2023.